Lista de obras -

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients

artículo científico publicado en 2006

Characterization and structural analysis of HIV-1 integrase conservation

artículo científico publicado en 2009

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution

artículo científico publicado en 2005

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance

artículo científico publicado en 2015

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes

artículo científico publicado en 2014

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

artículo científico publicado en 2014

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

artículo científico publicado en 2012

E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations

artículo científico publicado en 2011

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

artículo científico publicado en 2010

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes

artículo científico publicado en 2009

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs

artículo científico publicado en 2012

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies

artículo científico publicado en 2013

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

artículo científico publicado en 2008

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

artículo científico publicado en 2017

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

artículo científico publicado en 2008

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors

artículo científico publicado en 2014

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

artículo científico publicado en 2010

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance

artículo científico publicado en 2018

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen

artículo científico publicado en 2018

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma

artículo científico publicado en 2009

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

article

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

artículo científico publicado en 2008

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients

artículo científico publicado en 2007

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

artículo científico publicado en 2009

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

artículo científico publicado en 2009

Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir".

artículo científico publicado en 2018

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes

artículo científico publicado en 2009

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

artículo científico publicado en 2006

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

artículo científico publicado en 2010

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype

artículo científico publicado en 2011

Lista de obras de

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients

Characterization and structural analysis of HIV-1 integrase conservation

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir".

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype